Press release BoxID: 621346 (fme AG)
  • fme AG
  • Wolfenbütteler Straße 33
  • 38102 Braunschweig
  • Contact person
  • Tina Lenitzki
  • +49 (531) 23854 - 160

Pharmaceutical Company CSL Behring Draws on fme AG's Support in Rolling Out the QlikView Business Discovery Platform

(PresseBox) (Braunschweig, ) fme, a specialist in enterprise information management solutions, is supporting long-time customer CSL Behring, a global leader in the plasma protein biotherapeutics industry, in its efforts to introduce the QlikView Business Discovery platform. QlikView was initially evaluated in practical use at a 'seeing is believing' (SIB) event. On the back of positive reviews, fme and CSL Behring launched a pilot project on the basis of QlikView in 2012.

CSL Behring GmbH pursues a company-wide SAP® strategy, which also includes the corresponding standard modules for business intelligence (BI). However, these were unable to meet all of the special requirements posed by the pharmaceutical company.

As part of the pilot project with fme, the two companies began by setting up a quality and manufacturing data warehouse in the QA department. This would be used to evaluate the corresponding data and likewise allow future BI requirements in this area to be mapped and defined. Process- and quality-related data were imported into QlikView, where they serve as the basis for analyses that enable KPI reporting throughout all steps in the production process. Evaluations of process-related information in the production department, such as step yields and trend information from in-process controlling, supply up-to-date batch-specific values that are used to optimize individual production parameters.

"Companies operating in the field are required to maintain end-to-end documentation of step yields for use in the accompanying batch tracking due to the strict regulatory framework governing the pharmaceutical industry," explains Dennis Finger, project manager at CSL Behring. "QlikView delivers batch-specific values in accordance with our specifications that we in turn use to optimize various parameters within the process chain. This enables us to maintain the quality of our products, as it allows us to reliably calculate the step yields, analyze potential sources of loss, and take immediate steps in response as necessary," continues Finger.

"QlikView is the perfect solution for the process industry in the pharmaceutical industry," explains Andreas Buchholz, who heads the Business Intelligence department at fme AG. "Once the necessary conditions are in place, the program can be seamlessly integrated into the system landscape. QlikView also allows for flexible solutions that meet the requirements of the various departments at the pharmaceutical company to a tee."

Website Promotion

fme AG

We provide our customers with support in structuring and managing information more effectively and efficiently. To do so, we use enterprise content management, business intelligence, and product lifecycle management technologies. Our main focus is on solutions for life sciences and industrial manufacturing industry. We use best practice solutions and ensure optimal implementation to guarantee better decision making, faster processes, and increased quality and compliance. To this effect, fme provides vendor-independent consulting services, including access to our cost-effective near-shore resources where advisable. For more than ten years, renowned corporations like Audi, Boehringer Ingelheim, BMW, E.ON, Medtronic, RWE Dea, Sanofi-Aventis, and Volkswagen have relied our experience and competence. Managed by its original founders and owners, fme has enjoyed consistent growth over the years, a comfortable shareholder equity rate, and an uninterrupted profit development. With our reputed support processes and state-of-the-art product offering, we are well positioned to further expand our leading role.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit